The ASH 2024 conference has been buzzing with exciting developments in the field of hematology. As the conference comes to a close in San Diego, attendees are already looking forward to next year’s event in Orlando. Here is a recap of some of the most notable news from the conference:
The feud between Arcellx and Legend Biotech over their anti-BCMA CAR-T therapies for multiple myeloma has been making headlines. Arcellx received a special waiver to issue an early press release highlighting the lack of delayed neurotoxicity associated with its experimental treatment, anito-cel, in an attempt to disrupt Legend’s investor meeting. Legend, on the other hand, remains confident in its own therapy, Carvykti, which has already established itself as a standard-of-care treatment for multiple myeloma.
In a significant development for mantle cell lymphoma patients, a randomized trial has shown that autologous stem cell transplants may not be necessary for patients in deep remission after initial therapy. The results of the trial have reinforced the growing trend among clinicians to move away from transplants for these patients, as newer targeted and immune therapies have improved outcomes significantly.
Amgen’s Blincyto has shown promising results in improving disease-free survival in pediatric patients with acute lymphoblastic leukemia. The bispecific T-cell engager, when added to standard chemotherapy, significantly increased three-year disease-free survival rates in children with B-cell ALL. While the treatment may come with some risks, particularly infections, it has shown to be beneficial for high-risk populations.
For patients with chronic lymphocytic leukemia who have failed other treatments, Abbvie’s Epkinly, a bispecific T-cell engager, may offer a chance for complete remission. In a phase 1/2 trial, a significant number of patients responded to the drug, with some achieving a complete response. This is a promising development for CLL patients who have limited treatment options after relapse.
Overall, the ASH 2024 conference has showcased the latest advancements in hematology research and treatment options. From cutting-edge CAR-T therapies to promising new drug combinations, the future looks bright for patients with hematologic disorders. Stay tuned for more updates and breakthroughs in hematology as we look forward to next year’s conference in Orlando.
